BioCentury
ARTICLE | Clinical News

Caliber Biotherapeutics, ImmunGene preclinical data

July 1, 2013 7:00 AM UTC

In mouse xenograft models of non-Hodgkin's lymphoma (NHL), IGN002 achieved superior efficacy vs. rituximab and control fusion protein (p=0.002 and p<0.0001, respectively). In vitro, IGN002 showed stro...